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REVIEW
Pathogenesis of systemic lupus erythematosus
C C Mok, C S Lau
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J Clin Pathol 2003;56:481–490
The exact patho-aetiology of systemic lupus
erythematosus (SLE) remains elusive. An extremely
complicated and multifactorial interaction among
various genetic and environmental factors is probably
involved. Multiple genes contribute to disease
susceptibility. The interaction of sex, hormonal milieu,
and the hypothalamo–pituitary–adrenal axis modifies
this susceptibility and the clinical expression of the
disease. Defective immune regulatory mechanisms, such
as the clearance of apoptotic cells and immune
complexes, are important contributors to the
development of SLE. The loss of immune tolerance,
increased antigenic load, excess T cell help, defective B
cell suppression, and the shifting of T helper 1 (Th1) to
Th2 immune responses leads to B cell hyperactivity and
the production of pathogenic autoantibodies. Finally,
certain environmental factors are probably required to
trigger the disease.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Systemic lupus erythematosus (SLE) is a pro-totypic autoimmune disease characterisedby the production of antibodies to compo-
nents of the cell nucleus in association with a
diverse array of clinical manifestations. The
primary pathological findings in patients with
SLE are those of inflammation, vasculitis, im-
mune complex deposition, and vasculopathy. The
exact aetiology of SLE is unknown. SLE shows a
strong familial aggregation, with a much higher
frequency among first degree relatives of patients.
Moreover, in extended families, SLE may coexist
with other organ specific autoimmune diseases
such as haemolytic anaemia, immune thrombo-
cytopenic purpura, and thyroiditis. The concord-
ance of the disease in identical twins is approxi-
mately 25–50% and that in dizygotic twins is
around 5%.1 This suggests that genetic factors
play an important role in the predisposition of the
disease. However, most cases of SLE are sporadic
without identifiable genetic predisposing factors,
suggesting that multiple environmental or yet
unknown factors may also be responsible.
GENETIC SUSCEPTIBILITY
The concordance of SLE in identical twins, the
increase in frequency of SLE among first degree
relatives, and the increased risk of developing the
disease in siblings of SLE patients reflects a poly-
genic inheritance of the disease. Many different
genes contribute to disease susceptibility. In a
small proportion of patients (< 5%), a single gene
may be responsible. For instance, patients with
homozygous deficiencies of the early components
of complement are at risk of developing SLE or a
lupus-like disease.2 For most of the remaining
patients, multiple genes are required. It is
estimated that at least four susceptibility genes
are needed for the development of the disease.3
Of the genetic elements, the genes of the major
histocompatibility complex (MHC) have been
most extensively studied for their contribution to
human SLE. Population studies reveal that the
susceptibility to SLE involves human leucocyte
antigen (HLA) class II gene polymorphisms. An
association of HLA DR2 and DR3 with SLE is a
common finding in patients of different ethnici-
ties, with a relative risk for the development of
disease of approximately two to five.1 The HLA
class II genes have also been associated with the
presence of certain autoantibodies such as
anti-Sm (small nuclear ribonuclear protein),
anti-Ro, anti-La, anti-nRNP (nuclear ribonuclear
protein), and anti-DNA antibodies.3
“It is estimated that at least four
susceptibility genes are needed for the
development of the disease”
Among other MHC gene systems, inherited
complement deficiencies also influence disease
susceptibility. The HLA class III genes, particu-
larly those encoding complement components C2
and C4, confer risk for SLE in certain ethnic
groups. Patients with homozygous C4A null alle-
les, irrespective of the ethnic background, are at
high risk of developing SLE. Moreover, SLE is
associated with inherited deficiencies of C1q,
C1r/s, and C2.4 A decrease in complement activity
could promote disease susceptibility by impairing
the neutralisation and clearance of self and
foreign antigens. When the antigen burden over-
whelms the clearance capacity of the immune
system, autoimmunity may ensue.
In addition, many polymorphic non-MHC
genes have been reported to be associated with
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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SLE. These include genes that encode mannose binding
protein (MBP), tumour necrosis factor α, the T cell receptor,
interleukin 6 (IL-6), CR1, immunoglobulin Gm and Km allo-
types, FcγRIIA and FcγRIIIA (both IgG Fc receptors), and heat
shock protein 70.3 5 However, in most cases, consistent results
could not be obtained in subsequent studies in different eth-
nic groups. Some of these polymorphic genes may confer risk
to certain subsets of patients with SLE. For instance, the
FcγRIIA polymorphism has been associated with nephritis in
African Americans and Koreans,6 7 and the FcγRIIIA polymor-
phism with SLE in Hispanics and white populations.8 9 In
addition, mutations of codon 54 of the MBL gene carry a
minor risk for SLE susceptibility in southern Chinese.10
During the past few years, linkage analyses using SLE mul-
tiplex families have provided many chromosomal regions for
further exploration of susceptibility genes.11–14 Six regions
exhibiting significant linkage to SLE are promising. Studies
are under way to fine map these linked regions and to identify
the genes in the susceptibility regions. The discovery of multi-
ple chromosome regions conferring risk for SLE development
supports the notion that SLE is a polygenic disease. Table 1
summarises the genes that are involved in human SLE.
SEX, HORMONES, AND THE HYPOTHALAMO–
PITUITARY–ADRENAL AXIS
SLE is predominantly a female disease.15 First onset of SLE
before puberty and after menopause16 is uncommon. The
female predilection becomes less pronounced outside the
reproductive age range. In addition, patients with Klinefelter’s
syndrome, characterised by hypergonadotrophic hypogonad-
ism, are prone to the development of SLE.17 These observations
suggest a role for endogenous sex hormones in disease predis-
position.
Abnormal oestrogen metabolism has been demonstrated in
patients with SLE of both sexes, with an increase in
16α hydroxylation of oestrone, resulting in significantly raised
16α hydroxyestrone concentrations.18 The 16α metabolites are
more potent and feminising oestrogens.Women with SLE also
have low plasma androgens, including testosterone, dihy-
drotestosterone, dehydroepiandrosterone (DHEA), and dehy-
droepiandrosterone sulfate.19 20 This abnormality might be
explained by increased testosterone oxidation at C-1721 or
increased tissue aromatase activity.22 The concentrations of
androgens correlate inversely with disease activity.20 Low con-
centrations of plasma testosterone and raised luteinising hor-
mone (LH) values23 24 have been found in some men with SLE.
Thus, excessive oestrogenic but inadequate androgenic hor-
monal activity in both men and women with SLE might be
responsible for the alteration of the immune responses.
Table 2 summarises the actions of oestrogens on various cell
types of the immune system. Both physiological and
supraphysiological concentrations of oestrogens facilitate
humoral responses, leading to increased B cell proliferation
and antibody production.25–28 On the contrary, high doses of
oestrogens inhibit T cell responses, such as proliferation and
IL-2 production.29 30 Oestrogens also increase calcineurin
mRNA levels and enhance the cell surface expression of CD40
ligand (CD40L) in cultured T cells from patients with SLE.31 32
These effects appear to be unique to patients with SLE,
indicating that lupus T cells are more sensitive to oestrogens.
Taken together, oestrogens may aggravate SLE by prolonging
the survival of autoimmune cells, increasing T helper type 2
(Th2) cytokine production, and stimulating B cells to produce
autoantibodies. The inhibition of the Th1 response and the
enhancement of CD40L expression on lupus T cells may indi-
rectly promote the Th2 response and lead to further B cell
hyperactivity.
The effect of androgens on lymphocyte functions has been
less well studied. Testosterone reduces immunoglobulin
production from peripheral blood mononuclear cells of both
normal subjects and patients with SLE.33 34 DHEA has been
shown to be associated with enhancement of Th1 and inhibi-
tion of Th2 immune responses in both humans and mice.35 36
Table 1 Genes involved in human systemic lupus
erythematosus
HLA genes
DR2, DR3 (relative risk 2–5)
DR2, DR3, DR7, DQw1, DQw2, DQA1, DQB1, B8 (anti-Ro)
DR3, DR8, DRw12 (anti-La)
DR3, DQw2, DQA1, DQB1, B8 (anti-Ro and anti-La)
DR2, DR3, DR7, DQB1 (anti-DNA)
DR2, DR4, DQw5, DQw8, DQA1, DQB1 (anti-U1 ribonuclear
protein)
DR2, DR4, DR7, DQw6, B61 (anti-Sm)
DR4, DR7, DQ6, DQ7, DQw7, DQw8, DQw9 (anticardiolipin or
lupus anticoagulant)
Complement genes (C2, C4, C1q)
Non-HLA genes
Mannose binding lectin polymorphisms
Tumour necrosis factor α
T cell receptor
Interleukin 6
CR1
Immunoglobulin Gm and Km
FcγRIIA (IgG Fc receptor)
FcγRIIIA (IgG Fc receptor)
PARP (poly-ADP ribose polymerase)
Heat shock protein 70
Humhr 3005
HLA, human leucocyte antigen; Sm, Smith antigen.
Table 2 Effects of oestrogen on immune function25–30
Cell type Effect Dose
B cells ↑B cell differentiation and in vitro Ig production including anti-dsDNA (patients with SLE and
healthy subjects)
Physiological
↓In vitro apoptosis of PBMCs and ↓TNF-α production (patients with SLE, not in healthy subjects) Physiological
T cells ↓Proliferative response to mitogens and antigens High
↓IL-2R expression and IL-2 production in activated peripheral blood T cells (healthy subjects) High
↑Calcineurin mRNA values in cultured T cells (patients with SLE, not in healthy controls or patients
with other rheumatic diseases)
Dose dependent
↑CD40L expression of peripheral blood T cell (patients with SLE, not in healthy controls) Physiological
Monocytes ↑IL-10 production (patients with SLE and healthy subjects) Physiological
↑cNOS release Physiological
Others ↑Adhesion molecule expression in endothelial cells High
CD40L, CD40 ligand; cNOS, cytoplasmic nitric oxide synthase; dsDNA, double stranded DNA; Ig, immunoglobulin; IL, interleukin; IL-2R, interleukin 2
receptor; PMBC, peripheral blood mononuclear cells; SLE, systemic lupus erythematosus; TNF-α, tumour necrosis factor α.
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The opposite effects of oestrogens and androgens on the
immune system, coupled with unbalanced oestrogenic and
androgenic hormonal activity in patients with SLE, may help
explain some of the immune aberrations seen in this disease.
Epidemiological studies reveal an association between the
use of exogenous oestrogens and the onset of SLE. In a large
cohort of nurses as part of the Nurses’ Health Study, it was
shown that both the past use of oral contraceptive (OC) pills
and hormonal replacement therapy (HRT) was associated
with a slightly increased risk of SLE development.37 38
Moreover, a proportional increase in the risk of SLE related to
the duration of HRT was seen. A more recent case–control
study also reported an increased risk of the development of
SLE or discoid lupus in women receiving HRT for more than
two years when compared with non-users.39
There is evidence that endogenous oestrogen concentra-
tions may influence disease activity and prognosis in human
SLE. In the presteroid era, improvement of SLE was noted in
individual patients who had undergone menopause or
oophorectomy.40 Flares of SLE are well known to occur during
periods of rapid hormonal changes. These include pregnancy,
puerperium, ovulation stimulation during in vitro fertilisa-
tion, and exogenous oestrogen administration.41–44 Lupus
activity tends to be reduced when patients undergo
menopause.45 It has also been noted that in many women dis-
ease flares are more common during the second half of the
menstrual cycle, after the midcycle surge of oestrogen.46 The
administration of exogenous oestrogens in the form of OC
pills and HRT may exacerbate the disease in patients with
existing lupus.47–49 Furthermore, late onset SLE, defined as first
onset of disease after the age of 50, was reported have a more
benign disease course, with less serious organ involvement.50
Patients with SLE who have low female sex hormone values at
disease onset were found to have a lower relative mortality
risk when compared with age matched controls.51
Prolactin has recently been found to be an immunostimula-
tory hormone.52 The main origin is the anterior pituitary, but
lymphocytes are also capable of producing prolactin, which
serves as an autocrine or paracrine mediator.53 Chronic hyper-
prolactinaemia induced by syngeneic pituitary gland implan-
tation stimulates primary humoral antibody responses in
rats,54 and accelerates autoimmune phenomena in lupus prone
mice.55 Recent data suggest that the stimulatory actions of
oestrogens on autoreactive B cells require the presence of
prolactin.56
Hyperprolactinaemia has been demonstrated in a pro-
portion of patients with SLE of both sexes.57–64 Prolactin
concentrations correlate with disease activity in some
studies.58 64 Bromocriptine, a dopamine agonist that selectively
inhibits prolactin secretion from the pituitary, has been shown
to be useful in the treatment of non-life threatening SLE.65 66
However, the exact role of prolactin in SLE requires further
work because a positive correlation between lupus activity and
prolactin values cannot be demonstrated consistently.59 62–64
“There is evidence that endogenous oestrogen
concentrations may influence disease activity and
prognosis in human systemic lupus erythematosus”
Gonadotrophin releasing hormone (GnRH), a decapeptide
produced by the hypothalamus, regulates the release of LH
and follicle stimulating hormone from the anterior pituitary.
Recent animal studies show that GnRH is
immunostimulatory.67 In lupus prone mice, GnRH has been
shown to exacerbate lupus, but the effect appears to be sexu-
ally dimorphic.68 69 However, the role of GnRH in human SLE
requires further evaluation.
The hypothalamo–pituitary–adrenal (HPA) axis is the chief
component of the stress system. The stress induced increase in
serum concentrations of glucocorticoids is essential for the
prevention of autoreactive or unrestrained amplification of the
immune response, which results in self injury and autoimmu-
nity. A defective HPA axis may confer susceptibility to
autoimmune disorders. Female Lewis (LEW/N) rats, charac-
terised by a defective hypothalamic corticotrophin releasing
hormone (CRH) response to several immunological activators,
including IL-1,70 are highly susceptible to a wide variety of
experimental autoimmune disorders.
There is preliminary evidence that a defective HPA axis is
present in both murine and human lupus. A significantly
lower increase in plasma corticosterone concentrations upon
stimulation by recombinant IL-1 is seen in lupus prone (MRL/
lpr) mice.71 Aging of MRL/lpr mice, which is accompanied by
an increase in autoantibody production, is associated with a
decrease in hypothalamic CRHmRNA expression.72 Studies on
the function of the HPA axis in patients with SLE are limited
and often confounded by the effect of concomitant glucocorti-
coid treatment. A study on a group of active untreated female
patients with SLE reports that the cortisol response to induced
hypoglycaemia is significantly lower in patients than in
healthy controls, indicating that some degree of HPA axis dys-
function does exist.73 The dysregulated HPA axis in SLEmay be
responsible for disease susceptibility and progression.
Table 3 summarises the role of hormones in the pathogen-
esis of SLE. Hormones may not have a direct causative role in
SLE, but a milieu consisting of different values of
hypothalamo–pituitary and gonadal hormones may create an
endogenous environment for susceptible individuals to
develop the disease. Changes in the concentrations of sex
steroids, coupled with certain yet undiscovered environmental
factors, may lead to disease flares and serve to explain the
“wax and wane” nature of the disease.
Table 3 Role of hormones in human SLE
Susceptibility to SLE development
• Low endogenous oestrogen concentrations are protective
• Low androgen values in men increase risk
• Use of exogenous oestrogens increases risk in women
Hormonal profile and HPA axis in patients with SLE
• Increase in metabolism of oestrogen to more potent metabolites (both sexes)
• Low androgen values (both sexes). Androgen values correlate inversely with disease activity in women
• Hyperprolactinaemia occurs in a subset of patients (both sexes). Prolactin concentrations correlate with
disease activity in some studies. Bromocriptine is beneficial in mild SLE
• Preliminary evidence for a defective HPA axis in untreated female patients with SLE
Hormones, SLE activity, and prognosis
• Disease activity tends to reduce after menopause
• Flares of SLE may occur during periods of rapid hormonal changes
• Cyclical fluctuation of disease activity in women during the menstrual cycle
• Patients with postmenopausal onset SLE have lower disease activity and better prognosis
HPA, hypothalamus–pituitary–adrenal; SLE, systemic lupus erythematosus.
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IMMUNOPATHOLOGY
The basic pathological features of SLE are that of inflamma-
tion and blood vessel abnormalities, which include band or
occlusive vasculopathy, vasculitis, and immune complex depo-
sition. The best characterised organ pathology is in the kidney.
By light and immunofluorescence microscopy, renal biopsies
in patients with SLE display mesangial cell proliferation,
inflammation, basement membrane abnormalities, and im-
mune complex deposition, comprising immunoglobulins and
complement components. On electron microscopy, these
deposits can be visualised in the mesangium and the
subendothelial or subepithelial surface of the basement mem-
brane.
Other organ systems affected by SLE usually display
non-specific inflammation or vascular abnormalities, al-
though pathological findings are sometimes minimal. One
example is cortical microinfarcts and bland vasculopathy with
degenerative or proliferative changes in patients with central
nervous system disease. Inflammation and necrotising vascu-
litis can rarely be found. Occlusive vasculopathy is a common
histological feature associated with the presence of anti-
phospholipid antibodies. Atherosclerosis and tissue damage
caused by hypertension, corticosteroids, and other drugs can
be demonstrated in patients with long standing SLE.
Autoantibodies
The central immunological disturbance in patients with SLE is
autoantibody production. These antibodies are directed at
several self molecules found in the nucleus, cytoplasm, and
cell surface, in addition to soluble molecules such as IgG and
coagulation factors. Antinuclear antibodies are most charac-
teristic and present in more than 95% of patients. Anti-double
stranded DNA (ds-DNA) and anti-Sm antibodies are unique
to patients with SLE. In fact, their presence is included in the
classification criteria of SLE.74 The Sm antigen is designated as
a small nuclear ribonucleoprotein (snRNP) and is composed
of a unique set of uridine rich RNA molecules bound to a
common group of core proteins and other proteins associated
with the RNA molecules. Anti-Sm antibodies react with
snRNP core proteins, whereas anti-DNA antibodies bind to a
conserved nucleic acid determinant widely present on DNA.
Anti-DNA antibody titres frequently vary over time and
disease activity but anti-Sm antibody titres are usually
constant.
The most remarkable feature of anti-DNA antibodies is
their association with glomerulonephritis. Anti-DNA antibod-
ies can be isolated in an enriched form from glomerular
eluates of patients with active lupus nephritis and anti-DNA
antibodies can induce nephritis in normal and severe
combined immunodeficient mice.75 76 However, the correlation
between anti-DNA antibodies and lupus nephritis in not com-
plete because some patients with active nephritis are negative
for anti-DNA antibodies, whereas some patients with persist-
ent high titres of anti-DNA may not show renal involvement.
“The most remarkable feature of anti-DNA antibodies is
their association with glomerulonephritis”
Anti-DNA antibodies differ in their properties, including
isotype, ability to fix complement, and capacity to bind to the
glomeruli causing pathogenicity.75 Only certain types of
anti-DNA antibodies are pathogenic.77 The involvement of
anti-DNA antibodies in lupus nephritis is suggested by several
pieces of circumstantial evidence. First, clinical observations
in most patients indicate that active nephritis is associated
with raised anti-DNA titres and reduced total haemolytic
complement values.78 Second, anti-DNA antibodies show
preferential deposition in the kidneys, suggesting that
DNA–anti-DNA antibody immune complexes are the main
mediators of inflammation.79 Although renal injury may result
from immune complexes containing anti-DNA antibodies, cir-
culating immune complexes have been difficult to characterise
because of their low concentration in serum. The formation of
immune complexes in situ, instead of within the circulation,
may be another possibility. Anti-DNA antibodies may bind to
pieces of DNA adherent to the glomerular basement
membrane via the histones or interact with additional
glomerular antigens, such as C1q, nucleosomes, heparan sul-
fate, and laminin.80 The binding of anti-DNA antibodies to
these antigens may initiate local inflammation and comple-
ment activation, and may also anchor immune complexes to
the kidney sites, whether or not they are formed in the circu-
lation or in situ.
Although an association between certain clinical features of
SLE and autoantibodies such as anti-ribosomal P antibodies
and psychosis, and anti-Ro antibodies and congenital heart
block and subacute cutaneous lupus, has been well docu-
mented, the pathogenicity of these antibodies has not been
adequately studied. The exact immunological mechanisms for
injury remain to be elucidated. The pathogenesis of manifes-
tations other than glomerulonephritis is less well understood,
although immune complex deposition with activation of com-
plement at relevant sites is a probable mechanism. This is
demonstrated by the frequent association of hypocomplemen-
taemia and signs of vasculitis at the sites of active SLE. Direct
antibody mediated damage and cell mediated cytotoxicity on
target tissues are other possible mechanisms.
Disturbances of the immune response
SLE is characterised by a myriad of immune system
aberrations that involve B cells, T cells, and cells of the mono-
cytic lineage, resulting in polyclonal B cell activation,
increased numbers of antibody producing cells, hypergamma-
globulinaemia, autoantibody production, and immune com-
plex formation. It appears that excessive and uncontrolled T
cell help in the differentiation and activation of autoantibody
forming B cells is probably a final common pathway.
The activation of B and T cells requires stimulation by spe-
cific antigens. Irritating chemicals such as pristine, bacterial
DNA and cell wall phospholipids, and viral antigens can
induce anti-DNA antibodies in mice.77 Moreover, self antigens,
such as DNA–protein and RNA–protein complexes may
induce autoantibody production.81 Environmental antigens
and self antigens are taken up by professional antigen
presenting cells (APCs) or bind to induced antibodies on the
surface of B cells. Both professional APCs and B cells process
the antigens into peptides and present them to T cells through
their surface HLA molecules. The activated T cells in turn
stimulate the B cells to produce pathogenic autoantibodies. In
addition to contact stimulation, the interaction of B and T cells
is facilitated by several cytokines, such as IL-10, and requires
accessory molecules such as those of the CD40/CD40L and
B7/CD28/CTLA-4 systems to initiate a second signal.
“The number of B cells at all stages of activation is
increased in the peripheral blood of patients with active
systemic lupus erythematosus”
B cell activation is abnormal in patients with SLE. The
number of B cells at all stages of activation is increased in the
peripheral blood of patients with active SLE.82 These B cell
abnormalities can precede the development of SLE. Activated
lupus B cells have higher intracytoplasmic calcium responses
than controls.83 There is also evidence that B cells in patients
with SLE are more sensitive to the stimulatory effects of cyto-
kines such as IL-6 than non-SLE B cells.84 Moreover, the phe-
nomenon of epitope spreading has been demonstrated in both
human and murine SLE.85 Thus, it appears that B cells in
patients with SLE are more prone to polyclonal activation by
antigens, cytokines, and other stimuli.
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Abnormalities in T cell function are also evident in patients
with SLE. The total number of peripheral blood T cells is usu-
ally reduced, probably because of the effects of anti-
lymphocyte antibodies.86 There is a skewing of T cell function
towards B cell help, leading to enhanced antibody
production.87 Experiments have shown that the early events of
T cell activation are defective in patients with SLE compared
with controls.88 89 Although peripheral lupus T cells are
activated, both their capacity for proliferation in response to
mitogenic stimulation and IL-2 production are reduced.90–93
The reasons for the defective Th1 responses in SLE remain
speculative. Downregulation by excessive Th2 cytokines,
defective interaction between APCs and T cells, the suppres-
sive effects of CD8+ T cells and natural killer (NK) cells, the
presence of IL-2 inhibitors, and the downregulation of IL-2
receptors are possible mechanisms.94 95
Cytokine network in SLE
Cytokine profiles in patients with SLE have been studied
extensively and are summarised in table 4. Peripheral blood
mononuclear cells (PBMCs) from patients with SLE prolifer-
ate less than controls when stimulated with various antigens
and mitogens.90 Supernatants from phytohaemagglutinin
(PHA) or autologous mixed lymphocyte reaction stimulated
lupus T cells produce less IL-2 than control T cells. Lupus T
cells are less responsive to IL-2 stimulation than normal T
cells.91–93 However, the expression of IL-2 in freshly prepared
SLE PBMCs was increased compared with control PBMCs.96
Lupus T cells are capable of producing normal amounts of IL-2
in response to optimal stimulation with PHA combined with
phorbol esters or with anti-CD28 antibodies.94 97 As mentioned
previously, the impaired in vitro IL-2 production from lupus T
cells is probably the result of many factors, one of which is the
downregulating effects of certain Th2 cytokines.
The recent discovery of the role played by IL-10 in the
pathogenesis of SLE supports this hypothesis. IL-10 is a Th2
cytokine that acts as a potent stimulator of B cell proliferation
and differentiation, and thereby a potential mediator of poly-
clonal B cell activation in SLE. Indeed, recent studies have
shown that spontaneous production of IL-10 from SLE
peripheral blood B cells and monocytes is significantly higher
than that of controls.98 99 The expression of IL-10 transcripts is
significantly increased in the non-T cell population of PBMCs
from patients with SLE compared with controls.100 Moreover,
serum IL-10 concentrations are higher in patients with SLE
than in controls and are correlated with clinical and serologi-
cal disease activity, and anti-DNA antibody titres.101–103 Further-
more, an increased ratio of IL-10 to interferon γ secreting cells
in the PBMCs of patients with SLE correlates with disease
activity.104
The increase in IL-10 production may be a cause of the
defective in vitro Th1 response in lupus T cells. This is
suggested by a study demonstrating that the addition of
blocking antibodies to IL-10 significantly enhanced the prolif-
erative response of lupus PBMCs.105 Conversely, PBMCs from
patients with SLE and inactive disease cultured with IL-10
showed a significant augmentation of anti-DNA antibody
production.106
IL-12, a heterodimeric cytokine produced by B cells, macro-
phages, and dendritic cells, promotes cell mediated immune
responses but exerts some inhibitory activities on humoral
responses.107 IL-12 production was found to be impaired in
stimulated PBMCs from patients with SLE compared with
matched controls.108 109 The defect in IL-12 production probably
lies in the monocytes but not the B cells.110 In contrast, the
addition of IL-12 to lupus PBMCs significantly inhibits both
spontaneous and IL-10 stimulated immunoglobulin and anti-
DNA antibody production.111 Moreover, the production of anti-
DNA antibodies by PBMCs from patients with SLE and active
disease is inhibited by culturing the cells with IL-12.106 The
results from these studies suggest that dysregulation of the
IL-10–IL-12 balance plays a crucial role in the impaired cellu-
lar immune responses seen in patients with SLE.
Defective immune regulation
The clearing of immune complexes by phagocytic cells is
defective in patients with SLE.7 This results partly from the
reduced numbers of CR1 receptors for complement and func-
tional defects of the receptors on cell surfaces.112 113 Defective
clearance may also result from inadequate phagocytosis of
IgG2 and IgG3 containing complexes. Allelic polymorphisms
of the IgG receptors (FcγR) have recently been described.
Some of the polymorphic alleles (FcγRIIA and FcγRIIIA) are
associated with lower binding of the Fc portions of IgG2 and
IgG3, and hence impaired clearance of immune
complexes.7 114 Indeed, the FcγRIIA and FcγRIIIA genotypes
have been associated with susceptibility to SLE and nephritis
in certain ethnic groups.7–9 115 Although consistent results can-
not be obtained in patients of different ethnicities, impaired
immune complex clearance by phagocytes is an important
pathogenetic mechanism in SLE.
A recent study also demonstrated that non-inflammatory
engulfment phagocytosis of apoptotic cells is impaired in
patients with SLE.116 Persistently circulating apoptotic waste
may serve as an immunogen for the induction of autoreactive
lymphocytes and as an antigen for immune complex
formation.
“Impaired immune complex clearance by phagocytes is
an important pathogenetic mechanism in systemic lupus
erythematosus”
The synthesis and secretion of pathogenic autoantibodies
in SLE is driven by the interaction of CD4+ and CD8+ helper
T cells, and double negative T cells (CD4− CD8−) with B
cells.117 Therefore, cells that normally suppress B cell activa-
tion, such as CD8+ suppressor T cells and NK cells are defec-
tive in their suppressive activity. It has been shown that CD8+
T cells and NK cells from patients with active SLE are often
incapable of downregulating polyclonal immunoglobulin syn-
thesis and autoantibody production.87 One recent study
reported that CD8+ T suppressor cell function was impaired
Table 4 Cytokines in patients with SLE
IL-2
• ↑IL-2 expression in PBMCs
• ↑IL-2 mRNA expression in lymphocytes
• ↑Serum sIL-2 receptor expression
• ↓IL-2 production to antigenic and mitogenic stimulation in T cells
IL-6
• ↑IL-6 mRNA expression in PBMCs
• ↑IL-6 production in stimulated whole blood culture
• ↑Serum IL-6 concentrations
IL-10
• ↑Spontaneous IL-10 production in PBMCs
• ↑Ratio of IL-10:IFN-γ secreting cells in PBMCs
• ↑IL-10 mRNA expression in PBMCs
• ↑Serum IL-10 concentration and correlates with disease activity
IL-12
• Impaired production of IL-12 by stimulated PBMCs
• IL-12 supplementation inhibits Ig and anti-DNA production by
PBMCs
• IL-12 inhibits the action of IL-10 on PBMCs
Other cytokines
• ↑Serum IL-15, IL-16, and IL-18 concentrations
• ↑IFN-γ mRNA expression in PBMCs
• ↑Serum IFN-γ
IFN, interferon; Ig, immunoglobulin; IL, interleukin; PBMC, peripheral
blood mononuclear cell; sIL-2, soluble interleukin 2; SLE, systemic
lupus erythematosus.
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in patients with active SLE.118 This impaired suppression of B
cells may be one factor that leads to the perpetuation of the
disease.
In normal healthy subjects, overproduction of antibodies is
prevented by an idiotype network. This network is probably
defective in patients with SLE, leading to dysregulation of
autoantibody production.119
Table 5 summarises the abnormalities in the immune
response and immunoregulation in patients with SLE.
APOPTOSIS AND SLE
Apoptosis, or programmed cell death, is a process that leads to
the ordered destruction of cells, avoiding the release of intra-
cellular contents into the extracellular microenvironment,
where they have a powerful inflammatory effect. Defective
apoptosis leading to the prolonged survival of pathogenic
lymphocytes was thought to be one disease mechanism for
SLE. This hypothesis was supported by observations in murine
lupus models. MRL/lpr mice are characterised by the presence
of the lpr gene, which is associated with defective Fas (CD95)
receptors on the surface of lymphocytes. The interaction of Fas
and Fas ligand (FasL) transduces an active signal for cellular
apoptosis.120 Defective Fas mediated apoptosis in MRL/lpr mice
results in massive lymphoproliferation and the development
of a severe lupus-like disease with immune
glomerulonephritis.121 Gld/gld mice, characterised by a muta-
tion in the FasL gene leading to a non-functional FasL
molecule, also develop lymphoproliferation, hypergamma-
globulinaemia, and immunoglobulin deposits in the
kidneys.122
However, there are several problems with this model. First,
the massive lymphoproliferation resulting from defective
apoptosis seen in the MRL/lpr and Gld/gld mice is not charac-
teristic of human SLE, which conversely is often associated
with profound lymphopenia. Second, the expression of both
Fas and FasL is normal in patients with SLE.123 124 Lastly, apop-
tosis of peripheral lymphocytes in patients with SLE has been
shown to be increased compared with controls.125 126
The increased rate of apoptosis in SLE would theoretically
increase the chance of leakage of intracellular antigens that
may either trigger an autoimmune response or participate in
the formation of immune complexes. Under normal circum-
stances, apoptotic cells are engulfed by macrophages in the
early phase of apoptotic cell death without inducing inflam-
mation or the immune response. Recent studies have shown
that the clearance of apoptotic cells by macrophages in
patients with SLE is impaired.116 This is not confined to mono-
cytes andmacrophages of the peripheral blood, but also occurs
in the germinal centres of lymph nodes.127 128
The reasons for the defective clearance of apoptotic cells in
SLE are not clear. It could be the result of quantitative or
qualitative defects of the early complement proteins, such as
C2, C4, or C1q. Patients with homozygous deficiencies in these
complement components develop a severe lupus-like disease
early in life.129 The C1q receptors on the surface of phagocytes
constitute an extremely important mechanism for the
clearance of apoptotic cells.130 Patients or mice with homo-
zygous C1q deficiency develop autoantibodies and a lupus-like
syndrome apparently because of the inability to eliminate
apoptotic cells effectively, which leads to an increase in the
exposure of antigens to the immune system.129 131 Mice with a
targeted deletion of C1q show glomerulonephritis with
deposits of immune complexes and apoptotic cells in the
glomeruli.131
Anti-C1q antibodies can be found in a large proportion of
patients, particularly those with renal disease.132 This may
result in a functional deficiency of the receptor protein. It is
unlikely that anti-C1q antibodies represent the primary
abnormality in most patients with SLE, but they would
certainly provide a mechanism for persistence of the disease
and flares.133
Although bcl2 expression is increased in some lupus T cells,
the overall rate of lymphocyte apoptosis is increased in SLE.
Taken together with the impaired clearance mechanisms for
these apoptotic materials seen in patients with SLE, this may
predispose individuals to the development of antibodies
against nucleosomes, which contain materials such as
histones and dsDNA.
ENVIRONMENTAL TRIGGERS
Although genetic factors and the hormonal milieu may create
a predisposition towards SLE, the initiation of the disease
probably results from several environmental triggers and
exogenous factors (table 6). Infectious agents may induce
specific responses by molecular mimicry and disturb immu-
noregulation; diet affects the production of inflammatory
mediators; toxins/drugs modify cellular responsiveness and
immunogenicity of self antigens; and physical/chemical
agents, such as ultraviolet (UV) light, can cause inflammation,
induce cellular apoptosis, and cause tissue damage. The
impingement of these environmental triggers on predisposed
individuals is probably highly variable and could be a further
explanation for disease heterogeneity, in addition to its alter-
nating periods of flares and remission.
Table 5 Summary of abnormal immune responses and immunoregulation in patients
with SLE
Hyperactivated B cells
• Number of activated B cells producing Ig increased in peripheral blood
• B cell abnormalities are present in unaffected family members and may precede SLE development
• Lupus B cells are more prone to polyclonal activation by specific antigens
• Raised IL-6 and IL-10 concentrations may promote B cell hyperactivity
• B cell responses to activating signals are abnormal
Hyperactivated T cells
• Number of activated T cells increased in peripheral blood
• Abnormal early events of T cell activation
• T cell function skewed towards B cell help and Ig production
• Lupus T cells produce little IL-2 on stimulation
Abnormal phagocytic functions
• Phagocytic cells cannot bind or process immune complexes efficiently
• Phagocytosis of apoptotic cells impaired
Abnormal immunoregulation
• Defective clearance of immune complexes and apoptotic materials because of qualitative or quantitative
defects of early complement proteins (C2, C4, C1q), Fcγ, CR1, and C1q receptors on cell surfaces
• Suppressive activity of suppressor T cells and NK cells on activated T and B cell network is inadequate
• Idiotypic control of antibody production is dysregulated
Ig, immunoglobulin; IL, interleukin; NK, natural killer; SLE, systemic lupus erythematosus.
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Chemical/physical factors
Many drugs such as procainamide and hydralazine, which are
aromatic amines or hydrazines, can induce a lupus-like
syndrome, especially in individuals who are genetically slow
acetylators.134 Both aromatic amines and hydrazines, and their
derivatives, can be found in a wide variety of compounds used
in agriculture and industry, and commercial applications.
Hydrazine itself also occurs naturally in tobacco and tobacco
smoke. Lupus-like syndromes have been reported in individu-
als who have ingested or have been in contact with these
agents.135
Permanent hair colouring solutions contain aromatic
amines that can be absorbed through the scalp. Chronic use of
hair dyes has been associated with the development of SLE.136
However, subsequent studies did not confirm such an
association.135 137 138 A recent study reported only a weak
association between the risk of SLE and permanent hair dyes
or smoking.139
Exposure to sunlight is a well known environmental factor
in the induction and exacerbation of both cutaneous and sys-
temic lupus erythematosus. UV light, especially UVB, is an
important trigger in many patients with SLE. There is good
evidence that exposure of skin to UV light alters the location
and/or chemistry of DNA, in addition to Ro and nRNP
antigens, and probably enhances their immunogenicity.140
Recent studies have demonstrated that UV light induces the
apoptosis of human keratinocytes, leading to the formation of
clusters or blebs on the surface of dying cells, which contain
both nuclear and cytoplasmic antigens.141 142 This provides a
mechanism for the exposure of self antigens to the immune
system and provokes autoimmunity.
Dietary factors and infectious agents
Although several dietary factors and infectious agents are
implicated in the pathogenesis of SLE, none of these has been
consistently demonstrated in more than one study. The inges-
tion of alfalfa sprouts that contain L-canavanine has been
linked to the development of lupus-like symptoms in several
case reports.143 Infectious agents such as viruses might
theoretically initiate or cause a flare in SLE by activating B
cells, damaging tissues to release autoantigens, and triggering
the disease by molecular mimicry. However, viral “footprints”
have not been consistently demonstrated in the tissues of
patients with SLE.144 Thus, there is little evidence to support
that one infectious agent causes SLE, although this remains a
possibility and warrants further investigations.
Environmental oestrogens
The exposure of humans to environmental oestrogens is
believed to increase over the years through the consumption of
meat andmilk products of livestock that are fed with synthetic
oestrogens.145 146 Moreover, oestrogens are increasingly used by
postmenopausal women and for contraception. Chronic
oestrogen exposure in prepubertal non-immune mice has
been shown to influence thymic development and hence
immune tolerance.145 It is therefore plausible that exposure to
oestrogenic compounds during fetal life could be a potential
immunological hazard. In fact, prenatal diethylstilbesterol
Table 6 Environmental factors that may be relevant
in the pathogenesis of systemic lupus erythematosus
Chemical/physical factors
• Aromatic amines
• Hydrazines
• Drugs (procainamide, hydralazine, chlorpromazine, isoniazid,
phenytoin, penicillamine)
• Tobacco smoke
• Hair dyes
• Ultraviolet light
Dietary factors
• L-canavanine (alfalfa sprouts)
• High intake of saturated fats
Infectious agents
• ?Bacterial DNA/endotoxins
• ?Retroviruses
Hormones and environmental oestrogens
• Hormonal replacement therapy, oral contraceptive pills
• ?Prenatal exposure to oestrogens
Figure 1 The pathogenesis of systemic lupus erythematosus. APC,
antigen presenting cell.
Take home messages
• The patho-aetiology of systemic lupus erythematosus (SLE)
probably involves complicated and multifactorial interac-
tions among various genetic and environmental factors
• Multiple genes contribute to disease susceptibility, includ-
ing genes encoding complement and other components of
the immune response, in addition to major histocompatibil-
ity complex class I and II genes
• The interaction of sex, hormonal milieu (particularly oestro-
genic versus androgenic activity), and the hypothalamo–
pituitary–adrenal axis modifies this susceptibility and the
clinical expression of the disease
• Defective immune regulatory mechanisms, such as the
clearance of apoptotic cells and immune complexes, are
important contributors to the development of SLE
• The loss of immune tolerance, increased antigenic load,
excess T cell help, defective B cell suppression, and the
shifting of T helper 1 (Th1) to Th2 immune responses leads
to B cell hyperactivity and the production of pathogenic
autoantibodies
• In addition, environmental factors, such as chemicals and
drugs, ultraviolet light, dietary factors, viruses, and environ-
mental oestrogen are probably required to precipitate the
onset of the disease
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exposure has been linked to autoimmune disorders, although
further confirmation is needed.147 HRT and the use of OC pills
have also been associated with a small increase in the risk of
SLE development.37 38 Thus, environmental oestrogens and
endocrine disrupting chemicals may be important triggers for
autoimmunity in susceptible individuals. The ultimate devel-
opment of the disease will depend upon several factors, which
include genetic background, sex, age, dose and duration of
exposure, and immune status at the time of contact with these
agents.
SUMMARY
The pathogenesis of SLE is summarised diagrammatically in
fig 1. Multiple genes confer susceptibility to disease develop-
ment. Interaction of sex, hormonal milieu, the HPA axis, and
defective immune regulation, such as clearance of apoptotic
cells and immune complexes, modify this susceptibility. The
loss of immune tolerance, increased antigenic load, excess T
cell help, defective B cell suppression, and shifting of Th1 to
Th2 immune responses lead to cytokine imbalance, B cell
hyperactivity, and the production of pathogenic autoantibod-
ies. Finally, certain environmental factors are probably needed
to precipitate the onset of the disease.
. . . . . . . . . . . . . . . . . . . . .
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